Detalhe da pesquisa
1.
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition.
Int J Mol Sci
; 24(3)2023 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36768733
2.
DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia.
Int J Mol Sci
; 21(20)2020 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33081245
3.
Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
Haematologica
; 104(12): 2429-2442, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31004033
4.
Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.
Br J Haematol
; 172(3): 371-383, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26597680
5.
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.
Blood
; 123(14): 2139-47, 2014 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24501221
6.
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.
Blood
; 121(8): 1403-12, 2013 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-23243274
7.
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.
Blood
; 121(24): 4902-5, 2013 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23637131
8.
Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies.
Semin Cancer Biol
; 23(6): 422-30, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23665546
9.
High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.
Br J Haematol
; 165(5): 629-39, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24579978
10.
Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
Blood
; 124(25): 3831-3, 2014 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25498455
11.
Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
Haematologica
; 101(4): e135-8, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26819056
12.
Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic Leukaemia.
Cancers (Basel)
; 14(1)2021 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35008187
13.
Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis.
Hematol Oncol
; 31(1): 54-5, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22461140
14.
Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.
Br J Haematol
; 158(3): 426-9, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22571487
15.
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.
Cancer Cell
; 27(4): 516-32, 2015 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25873174
16.
Molecular bases of chronic lymphocytic leukemia in light of new treatments.
Immunol Lett
; 155(1-2): 51-5, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24103588
17.
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.
J Exp Med
; 209(9): 1537-51, 2012 Aug 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-22891273
18.
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia.
Leuk Lymphoma
; 54(5): 1087-90, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23039309